<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Annals of Clinical and Experimental Neurology</journal-id><journal-title-group><journal-title xml:lang="en">Annals of Clinical and Experimental Neurology</journal-title><trans-title-group xml:lang="ru"><trans-title>Анналы клинической и экспериментальной неврологии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2075-5473</issn><issn publication-format="electronic">2409-2533</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1097</article-id><article-id pub-id-type="doi">10.17816/ACEN.1097</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Original articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Оригинальные статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Serum Cholinesterase Activity in Elderly Female Patients with Different Screening Cognitive Status and Frailty Assessment Scores</article-title><trans-title-group xml:lang="ru"><trans-title>Активность сывороточной холинэстеразы у пожилых пациенток с различными скрининговыми показателями оценки когнитивного статуса и старческой астении</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3978-8902</contrib-id><name-alternatives><name xml:lang="en"><surname>Kodincev</surname><given-names>Anton N.</given-names></name><name xml:lang="ru"><surname>Кодинцев</surname><given-names>Антон Николоаевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>general neurologist, ultrasound specialist, junior researcher</p></bio><bio xml:lang="ru"><p>врач-невролог, врач ультразвуковой диагностики поликлиники, м. н. с.</p></bio><email>antonkodintsev@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2478-727X</contrib-id><name-alternatives><name xml:lang="en"><surname>Volkova</surname><given-names>Larisa I.</given-names></name><name xml:lang="ru"><surname>Волкова</surname><given-names>Лариса Ивановна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Dr. Sci. (Med.), Associate Professor, Chief freelance neurologist of the Ural Federal District, Head, Department of nervous diseases, neurosurgery and medical genetics</p></bio><bio xml:lang="ru"><p>д-р мед. наук, доцент, главный внештатный специалист-невролог Уральского федерального округа, зав. каф. нервных болезней, нейрохирургии и медицинской генетики</p></bio><email>antonkodintsev@mail.ru</email><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Institute of High Temperature Electrochemistry</institution></aff><aff><institution xml:lang="ru">Институт высокотемпературной электрохимии</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Ural State Medical University</institution></aff><aff><institution xml:lang="ru">Уральский государственный медицинский университет</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2024-12-06" publication-format="electronic"><day>06</day><month>12</month><year>2024</year></pub-date><volume>18</volume><issue>4</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>27</fpage><lpage>37</lpage><history><date date-type="received" iso-8601-date="2024-02-22"><day>22</day><month>02</month><year>2024</year></date><date date-type="accepted" iso-8601-date="2024-07-29"><day>29</day><month>07</month><year>2024</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2024, Kodincev A.N., Volkova L.I.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2024, Кодинцев А.Н., Волкова Л.И.</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="en">Kodincev A.N., Volkova L.I.</copyright-holder><copyright-holder xml:lang="ru">Кодинцев А.Н., Волкова Л.И.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://annaly-nevrologii.com/pathID/article/view/1097">https://annaly-nevrologii.com/pathID/article/view/1097</self-uri><abstract xml:lang="en"><p>Introduction. Frailty and mild cognitive impairment (MCI) are common geriatric syndromes. Peripheral serum cholinesterase (pChE) is a laboratory indicator that may reflect dysfunction of cholinergic processes in the central nervous system. Published data demonstrate the potential utility of pChE as a marker for a range of neurodegenerative disorders.</p> <p>Aim. This study aimed to identify and investigate the relationship between serum pChE levels in patients and various screening scores of cognitive status, frailty, and metabolic parameters.</p> <p>Materials and methods. The study included 50 women aged over 60 years. Screening clinical examinations were conducted, including Montreal Cognitive Assessment (MoCA), Mini-Mental State Examination (MMSE), Frontal Assessment Battery (FAB), Age Is Not a Hindrance questionnaire, and Charlson Comorbidity Index. A blood chemistry analysis was performed, including a kinetic colorimetric assay of serum pChE.</p> <p>Results. The Age Is Not a Hindrance score and pChE activity exhibited a moderate inverse correlation with a Spearman coefficient (rS) of –0.31; 95% confidence interval (CI) –0.5 to –0.03; p &lt; 0.05. The MoCA scores and pChE levels also showed a moderate inverse correlation with rS of –0.32; 95% CI: –0.55 to –0.05, p &lt; 0.05. A high risk of MCI is defined by a pChE activity threshold point of 9978 U/L, with a sensitivity of 47% and a specificity of 97%. The association between pChE activity and the prevalence of cognitive impairment remained significant even when different socio-demographic and metabolic parameters were included in the regression model, odds ratio (OR) 1.0005; 95% CI: 1.0001–1.009; p = 0.01).</p> <p>Conclusion. Women over 60 years of age in an outpatient setting exhibited an inverse correlation between the Age Is Not a Hindrance questionnaire score and the pChE activity. A pChE activity of 9978 U/L or higher was associated with an elevated risk of concomitant mild cognitive impairment. However, it is important to consider the high probability of false negatives in this context. This association persisted across a variety of clinical and metabolic factors.</p></abstract><trans-abstract xml:lang="ru"><p>Введение. Старческая астения (СА) и умеренные когнитивные нарушения (УКН) являются распространёнными гериатрическими синдромами. Периферическая холинэстераза (ПХЭ) сыворотки крови является потенциальным лабораторным показателем, отражающим дисфункцию холинергических процессов в центральной нервной системе. Опубликованы данные, свидетельствующие о возможности использования ПХЭ в качестве маркера различных нейродегенеративных заболеваний.</p> <p>Цель — выявление и изучение взаимосвязи активности ПХЭ сыворотки крови у пациенток с различными скрининговыми показателями когнитивного статуса, СА и метаболических параметров.</p> <p>Материалы и методы. В исследование были включены 50 женщин старше 60 лет. Проведено скрининговое клиническое обследование: Монреальская когнитивная шкала, Краткая шкала оценки когнитивного статуса, батарея тестов на лобную дисфункцию, опросник «Возраст не помеха», индекс коморбидности Чарлсона. Выполнено биохимическое обследование, включавшее определение ПХЭ сыворотки крови кинетическим колориметрическим методом.</p> <p>Результаты. Показатели опросника «Возраст не помеха» и активность ПХЭ обладают обратной умеренной корреляцией, коэффициент Спирмена (rS) = –0,31, 95% доверительный интервал (ДИ): –0,54–(–0,03); p &lt; 0,05. Показатели шкалы MoCA и активность ПХЭ также обладали умеренной обратной корреляцией: rS = –0,32; 95% ДИ –0,55–(–0,05); p &lt; 0,05. Пороговая точка активности ПХЭ 9978 ЕД/л позволяет с чувствительностью 47% и специфичностью 97% определить высокий риск умеренных когнитивных нарушений. Ассоциация между показателями ПХЭ и распространённостью когнитивных нарушений сохранялась при введении в регрессионную модель социально-демографических и метаболических параметров: отношение шансов 1,0005; 95% ДИ 1,0001–1,009; p = 0,01.</p> <p>Заключение. У женщин старше 60 лет, наблюдающихся амбулаторно, выявлена обратная корреляция показателей опросника «Возраст не помеха» и активности ПХЭ. Уровень активности ПХЭ 9978 ЕД/л и выше ассоциировался с высоким риском сопутствующих умеренных когнитивных нарушений, при этом важно учитывать большую вероятность ложноотрицательных результатов. Данная ассоциация сохранялась в условиях воздействия различных клинических и метаболических факторов.</p></trans-abstract><kwd-group xml:lang="en"><kwd>frailty</kwd><kwd>cognitive impairment</kwd><kwd>cholinesterase</kwd><kwd>biomarker</kwd><kwd>diagnosis</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>старческая астения</kwd><kwd>когнитивные нарушения</kwd><kwd>холинэстераза</kwd><kwd>биомаркер</kwd><kwd>диагностика</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution xml:lang="en">Ministry of Education and Science of the Russian Federation</institution></institution-wrap><institution-wrap><institution xml:lang="ru">Минобрнауки России</institution></institution-wrap></funding-source></award-group></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Proietti M., Cesari M. Frailty: what is it? Adv. Exp. Med. Biol. 2020; 1216:1–7. DOI: 10.1007/978-3-030-33330-0_1</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Tembo M.C., Mohebbi M., Holloway-Kew K.L. et al. The predictability of frailty associated with musculoskeletal deficits: a longitudinal study. Calcif. Tissue Int. 2021;109(5):525–533. DOI: 10.1007/s00223-021-00865-w</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Grande G., Haaksma M.L., Rizzuto D. et al. Co-occurrence of cognitive impairment and physical frailty, and incidence of dementia: systematic review and meta-analysis. Neurosci. Biobehav. Rev. 2019;107:96–103. DOI: 10.1016/j.neubiorev.2019.09.001</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Zheng L., Li G., Gao D. et al. Cognitive frailty as a predictor of dementia among older adults: a systematic review and meta-analysis. Arch. Gerontol. Geriatr. 2020;87:103997. DOI: 10.1016/j.archger.2019.103997</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Zhang T., Ren Y., Shen P. et al. Prevalence and associated risk factors of cognitive frailty: a systematic review and meta-analysis. Front. Aging Neurosci. 2022;13:755926. DOI: 10.3389/fnagi.2021.755926</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Jack C.R. Jr., Bennett D.A., Blennow K. et al. A/T/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology. 2016;87(5):539–547. DOI: 10.1212/WNL.0000000000002923</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Kodintsev A.N., Kovtun O.P., Volkova L.I. Saliva biomarkers in diagnostics of early stages of Alzheimer’s disease. Neurochem. J. 2020;14:429–438. DOI: 10.1134/S1819712420040042</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>von Bernhardi R., Alarcón R., Mezzano D. et al. Blood cells cholinesterase activity in early stage Alzheimer's disease and vascular dementia. Dement. Geriatr. Cogn. Disord. 2005;19(4):204–212. DOI: 10.1159/000083500</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Yu R., Ye X., Wang X. et al. Serum cholinesterase is associated with incident diabetic retinopathy: the Shanghai Nicheng cohort study. Nutr. Metab. (Lond). 2023;20(1):26. DOI: 10.1186/s12986-023-00743-2</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Chen H.Y., Wang W.W., Chaou C.H. et al. Prognostic value of serial serum cholinesterase activities in organophosphate poisoned patients. Am. J. Emerg. Med. 2009;27(9):1034–1039. DOI: 10.1016/j.ajem.2008.07.006</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Hubbard R.E., O'Mahony M.S., Calver B.L. et al. Plasma esterases and inflammation in ageing and frailty. Eur. J. Clin. Pharmacol. 2008;64(9):895–900. DOI: 10.1007/s00228-008-0499-1</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Szilágyi A.K., Németh A., Martini E. et al. Serum and CSF cholinesterase activity in various kinds of dementia. Eur. Arch. Psychiatry Neurol. Sci. 1987;236(5):309–311. DOI: 10.1007/BF00380958</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Karami A., Darreh-Shori T., Schultzberg M. et al. CSF and plasma cholinergic markers in patients with cognitive impairment. Front. Aging Neurosci. 2021;13:704583. DOI: 10.3389/fnagi.2021.704583</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Бельдиев С.Н., Андреева Е.В., Березина Е.И. и др. Целесообразность скрининга синдрома старческой астении у пожилых пациентов с артериальной гипертензией: возраст не помеха? Медицина. 2021;9(1):36–57. Bel'diev S.N., Andreeva E.V., Berezina E.I. et al. Feasibility of screening for frailty in elderly patients with arterial hypertension: age is not a hindrance? Medicine. 2021;9(1):36–57. DOI: 10.29234/2308-9113-2021-9-1-36-57</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Ткачева О.Н., Котовская Ю.В., Рунихина Н.К. и др. Клинические рекомендации «Старческая астения». Российский журнал гериатрической медицины. 2020;(1):11–46. Tkacheva O.N., Kotovskaya Yu.V., Runikhina N.K. et al. Clinical guidelines frailty. Russian Journal of Geriatric Medicine. 2020;1:11–46. DOI: 10.37586/2686-8636-1-2020-11-46</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Ткачева О.Н., Рунихина Н.К., Остапенко В.С. и др. Валидация опросника для скрининга синдрома старческой астении в амбулаторной практике. Успехи геронтологии. 2017;30(2):236–242. Tkacheva O.N., Runikhina N.K., Ostapenko V. S. et al. Validation of the questionnaire for screening frailty. Advances in Gerontology. 2017;30(2):236–242.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Schmidt E., Henkel E., Klauke R. et al. Proposal for standard methods for the determination of enzyme catalytic concentrations in serum and plasma at 37 degrees C. J. Clin. Chem. Clin. Biochem. 1990;28(10):805–808.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Ciesielska N., Sokołowski R., Mazur E. et al. Is the Montreal Cognitive Assessment (MoCA) test better suited than the Mini-Mental State Examination (MMSE) in mild cognitive impairment (MCI) detection among people aged over 60? Meta-analysis. Psychiatr. Pol. 2016;50(5):1039–1052. DOI: 10.12740/PP/45368</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Heppner H.J., Bauer J.M., Sieber C.C. et al. Laboratory aspects relating to the detection and prevention of frailty. Int. J. Prev. Med. 2010;1(3):149–157.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Sugimoto T., Arai H., Sakurai T. An update on cognitive frailty: its definition, impact, associated factors and underlying mechanisms, and interventions. Geriatr. Gerontol. Int. 2022;22(2):99–109. DOI: 10.1111/ggi.14322</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Bakhtiari S., Moghadam N.B., Ehsani M. et al. Can salivary acetylcholinesterase be a diagnostic biomarker for Alzheimer? J. Clin. Diagn. Res. 2017;11(1):ZC58–ZC60. DOI: 10.7860/JCDR/2017/21715.9192</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Smith R.C., Ho B.T., Hsu L. et al. Cholinesterase enzymes in the blood of patients with Alzheimer's disease. Life Sci. 1982;30(6):543–546. DOI: 10.1016/0024-3205(82)90267-3</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Hosoi M., Hori K., Konishi K. et al. Plasma cholinesterase activity in Alzheimer's disease. Neurodegener. Dis. 2015;15(3):188–190. DOI: 10.1159/000381532</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Jasiecki J., Targońska M., Wasąg B. The role of butyrylcholinesterase and iron in the regulation of cholinergic network and cognitive dysfunction in Alzheimer's disease pathogenesis. Int. J. Mol. Sci. 2021;22(4):2033. DOI: 10.3390/ijms22042033</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Summerbell J., Wynne H., Hankey C.R. et al. The effect of age and frailty upon blood esterase activities and their response to dietary supplementation. Br. J. Clin. Pharmacol. 1993;36(5):399–404. DOI: 10.1111/j.1365-2125.1993.tb00387.x</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Annapurna V., Senciall I., Davis A.J. et al. Relationship between serum pseudocholinesterase and triglycerides in experimentally induced diabetes mellitus in rats. Diabetologia. 1991;34(5):320–324. DOI: 10.1007/BF00405003</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Zilliox L.A., Chadrasekaran K., Kwan J.Y. et al. Diabetes and cognitive impairment. Curr. Diab. Rep. 2016;16(9):87. DOI: 10.1007/s11892-016-0775-x</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Mushtaq G., Greig N.H., Khan J.A. et al. Status of acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease and type 2 diabetes mellitus. CNS Neurol. Disord. Drug Targets. 2014;13(8):1432–1439. DOI: 10.2174/1871527313666141023141545</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Dong M.X., Xu X.M., Hu L. et al. Serum butyrylcholinesterase activity: a biomarker for Parkinson's disease and related dementia. Biomed. Res. Int. 2017;2017:1524107. DOI: 10.1155/2017/1524107</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Chen Y.C., Chou W.H., Fang C.P. et al. Serum level and activity of butylcholinesterase: a biomarker for post-stroke dementia. J. Clin. Med. 2019;8(11):1778. DOI: 10.3390/jcm8111778</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Журавин И.А., Наливаева Н.Н., Козлова Д.И. и др. Активность холин-эстераз и неприлизина плазмы крови как потенциальные биомаркеры синдрома мягкого когнитивного снижения и болезни Альцгеймера. Журнал неврологии и психиатрии им. С.С. Корсакова. 2015;115(12):110–117. Zhuravin I.А., Nalivaeva N.N., Kozlova D.I. et al. The activity of blood serum cholinesterases and neprilysin as potential biomarkers of mild-cognitive impairment and Alzheimer's disease. Zh. Nevrol. Psikhiatr. Im. S.S. Korsakova. 2015;115(12):110–117. DOI: 10.17116/jnevro2015115112110-117</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Бугрова С.Г., Новиков А.Е. Когнитивные расстройства при дискуляторной энцефалопатии и нейромедиаторные нарушения. Клиническая геронтология. 2007;13(11):38–42. Bugrova S.G., Novikov A.E. Cognitive disorders in case of dyscirculatory encephalopathy and neuromediate disturbance. Clinical gerontology. 2007;13(11):38–42.</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Josviak N.D., Batistela M.S., Souza R.K.M. et al. Plasma butyrylcholinesterase activity: a possible biomarker for differential diagnosis between Alzheimer's disease and dementia with Lewy bodies? Int. J. Neurosci. 2017;127(12):1082–1086. DOI: 10.1080/00207454.2017.1329203</mixed-citation></ref></ref-list></back></article>
